Factors affecting quality of life in epidermolysis bullosa

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 3, 2010, Pages 329-338

  Pagliarello, Calogero ^a   Tabolli, Stefano ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

disability; epidermolysis bullosa; health outcome; quality of life; rare disease

Indexed keywords

CAREGIVER; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EPIDERMOLYSIS BULLOSA; HEALTH CARE; HUMAN; LIFE EXPECTANCY; MORBIDITY; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SELF EVALUATION; SOCIAL ASPECT; WELLBEING; HEALTH CARE POLICY; HEALTH CARE QUALITY; PATHOPHYSIOLOGY; PSYCHOLOGY;

CAREGIVERS; EPIDERMOLYSIS BULLOSA; HEALTH POLICY; HUMANS; QUALITY OF HEALTH CARE; QUALITY OF LIFE;

EID: 77953690538     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.28     Document Type: Review

References (59)

1. Fine JD, Johnson LB, Suchindran C et al. The epidemiology of inherited EB: findings within American, Canadian, and European study populations. In: Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances, and the Findings of the National Epidermolysis Bullosa Registry. Fine JD, Bauer EA, McGuire J, Moshell A (Eds). Johns Hopkins University Press, MD, USA 101-113 (1999).
2. Horn HM, Priestley GC, Eady RA, Tidman MJ. The prevalence of epidermolysis bullosa in Scotland. Br. J. Dermatol. 136(4), 560-564 (1997).
3. McKenna KE, Walsh MY, Bingham EA. Epidermolysis bullosa in Northern Ireland. Br. J. Dermatol. 127, 318-321 (1992).
4. Kero M. Occurrence of epidermolysis bullosa in Finland. Acta Derm. Venereol. 64, 57-62 (1984).
5. Pavicic Z, Kmet-Vizintin P, Kansky A, Dobric I. Occurrence of hereditary bullosa epidermolyses in Croatia. Paediatr. Dermatol. 7, 108-110 (1990).
6. Tadini G, Gualandri L, Colombi M et al. The Italian registry of hereditary epidermolysis bullosa. G Ital. Dermatol. Venereol. 140, 359-372 (2005).
7. Langan SM, Williams HC. A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa. Clin. Exp. Dermatol. 34(1), 20-25 (2009).
8. Tolar J, Ishida-Yamamoto A, Riddle M et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113(5), 1167-1174 (2009).
9. Chino T, Tamai K, Yamazaki T et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am. J. Pathol. 173(3), 803-814 (2008).
10. De Luca M, Pellegrini G, Mavilio F. Gene therapy of inherited skin adhesion disorders: a critical overview. Br. J. Dermatol. 161(1), 19-24 (2009).
11. Fine JD, Eady RA, Bauer EA et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J. Am. Acad. Dermatol. 58(6), 931-950 (2008).
12. Fine JD, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J. Pediatr. 152(2), 276-280 (2008).
13. Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatol. Clin. 28(1), 159-164 (2010).
14. Shivaswamy KN, Sumathy TK, Shyamprasad AL, Ranganathan C. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl. Int. J. Dermatol. 48(7), 731-733 (2009).
15. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J. Am. Acad. Dermatol. 60(2), 203-211 (2009).
16. Souza CS, Felício LB, Bentley MV et al. Topical photodynamic therapy for Bowen's disease of the digit in epidermolysis bullosa. Br. J. Dermatol. 153(3), 672-674 (2005).
17. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 219(1), 80-83 (2009).
18. Saxena A, Lee JB, Humphreys TR. Mohs micrographic surgery for squamous cell carcinoma associated with epidermolysis bullosa. Dermatol. Surg. 32(1), 128-134 (2006).
19. Fine JD. Possible role for sentinel node biopsy in the management of squamous cell carcinomas in inherited epidermolysis bullosa. Arch. Dermatol. 140, 1012-1013 (2004).
20. Rokunohe A, Nakano H, Aizu T et al. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa. J. Dermatol. 35(6), 336-340 (2008).
21. Perez-Naranjo L, Herrera-Saval A, Garcia-Bravo B, Perez-Bernal AM, Camacho F. Sentinel lymph node biopsy in recessive dystrophic epidermolysis bullosa and squamous cell carcinoma. Arch. Dermatol. 141(1), 110-111 (2005).
22. Fine JD, Johnson LB, Weiner M, Stein A, Suchindran C. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a Phase 1 trial of systemic isotretinoin. J. Am. Acad. Dermatol. 50(4), 563-571 (2004).
23. Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity Score: development and validation. Br. J. Dermatol. 160(5), 1057-1065 (2009).
24. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc. Sci. Med.. 41, 1403-1409 (1995).
25. Jenkinson C, Coulter A, Wright L. Short form 36 (SF-36) health survey questionnaire: normative data for adults of working age. BMJ 306, 1437-1440 (1993).
26. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210-216 (1994).
27. Chren MM, Lasek RJ, Flocke SA et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin disease. Arch. Dermatol. 133, 1433-1440 (1997).
28. Chren MM, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J. Invest. Dermatol. 108, 103-107 (1997).
29. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16, 199-208 (1990).
30. Dietz MJ. A day in the life of a patient with DDEB. J. Am. Acad. Dermatol. 51(1 Suppl.), S58-S59 (2004).
31. Hall S. Life, epidermolysis bullosa and chasing tornadoes. J. Wound Care 13, 405-406 (2004).
32. van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CG, Jonkman MF. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm. Venereol. 88(2), 143-150 (2008).
33. Banky JP, Sheridan AT, Storer EL, Marshman G. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch. Dermatol. 140(7), 794-796 (2004).
34. Calikoglu E, Anadolu R. Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. Acta Derm. Venereol. 82(5), 380-382 (2002)
35. Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin. Exp. Dermatol. 29(2), 122-127 (2004).
36. Andreoli E, Mozetta A, Angelo C, Paradisi M, Foglio Bonda PG. Epidermolysis bullosa. Psychological and psychosocial aspects. Dermatol. Psychosom. 3, 77-81 (2002).
37. Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin. Exp. Dermatol. 27(8), 707-710 (2002).
38. Frew JW, Murrell DF. Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care. Dermatol. Clin. 28(1), 185-190 (2010).
39. Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br. J. Dermatol. 161(6), 1323-1330 (2009).
40. Tabolli S, Sampogna F, Di Pietro C et al. Quality of life in patients with epidermolysis bullosa. Br. J. Dermatol. 161(4), 869-877 (2009).
41. Sampogna F, Picardi A, Chren MM et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom. Med. 66, 620-624 (2004).
42. Lansdown R, Atherton D, Dale A, Sproston S, Lloyd J. Practical and psychological problems for parents and children with epidermolysis bullosa. Child Care Health Dev. 12, 251-256 (1986).
43. Fine JD, Johnson LB, Weiner M, Suchindran C. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size. Br. J. Dermatol. 152(5), 1009-1014 (2005).
44. van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis KG, Jonkman MF. The main problems of parents of a child with epidermolysis bullosa. Qual. Health Res. 18(4), 545-556 (2008).
45. Fine JD. Epidermolysis bullosa. Application of epidemiologic principles to the study of a group of rare diseases via a disease registry. Dermatol. Clin. 13(3), 659-670 (1995).
46. Fine JD, Johnson LB, Weiner M, Suchindran C. Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the National Epidermolysis Bullosa Registry. J. Pediatr. Gastroenterol. Nutr. 46(2), 147-158 (2008).
47. Freeman EB, Köglmeier J, Martinez AE et al. Gastrointestinal complications of epidermolysis bullosa in children. Br. J. Dermatol. 158(6), 1308-1314 (2008).
48. Fine JD, Hall M, Weiner M, Li KP, Suchindran C. The risk of cardiomyopathy in inherited epidermolysis bullosa. Br. J. Dermatol. 159(3), 677-682 (2008).
49. Fine JD, Johnson LB, Weiner M, Suchindran C. Tracheolaryngeal complications of inherited epidermolysis bullosa: cumulative experience of the national epidermolysis bullosa registry. Laryngoscope 117(9), 1652-1660 (2007).
50. Fine JD, Johnson LB, Weiner M et al. Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry. Am. J. Ophthalmol. 138(2), 254-262 (2004).
51. Figueira EC, Murrell DF, Coroneo MT. Ophthalmic involvement in inherited epidermolysis bullosa. Dermatol. Clin. 28(1), 143-152 (2010).
52. Chan SM, Dillon MJ, Duffy PG, Atherton DJ. Nephro-urological complications of epidermolysis bullosa in paediatric patients. Br. J. Dermatol. 156(1), 143-147 (2007).
53. Burgu B, Duffy PG, Wilcox DT. Single-centre experience of genitourinary complications of epidermolysis bullosa. J. Pediatr. Urol. 2(6), 583-586 (2006).
54. Fine JD, Johnson LB, Weiner M et al. Genitourinary complications of inherited epidermolysis bullosa: experience of the national epidermylosis bullosa registry and review of the literature. J. Urol. 172(5 Pt 1), 2040-2044 (2004).
55. Hata D, Miyazaki M, Seto S et al. Nephrotic syndrome and aberrant expression of laminin isoforms in glomerular basement membranes for an infant with Herlitz junctional epidermolysis bullosa. Pediatrics 116(4), E601-E607 (2005).
56. Farhi D, Ingen-Housz-Oro S, Ducret F et al. Recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) with IgA nephropathy: 4 cases. Ann. Dermatol. Venereol. 131(11), 963-967 (2004).
57. Fine JD, Johnson LB, Weiner M et al. Inherited epidermolysis bullosa and the risk of death from renal disease: experience of the National Epidermolysis Bullosa Registry. Am. J. Kidney Dis. 44(4), 651-660 (2004).
58. Fine JD. Epidermolysis Bullosa. In: Dermatology. Bolognia JL, Jorizzo JL, Rapini RP (Eds). Mosby, MO, USA 491-500 (2003).
59. DebRA International www.debra-international.org/